← Back to Search

Cementless Hip Replacement

Trident II Tritanium Acetabular Shell for Revision in Hip Revision Surgery

N/A
Waitlist Available
Research Sponsored by Stryker Orthopaedics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks, 3-6 months, 1 year and 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare the long-term outcomes of two types of hip replacement surgeries.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks, 3-6 months, 1 year and 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks, 3-6 months, 1 year and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Cases Free From Trident II Acetabular Shell Revision
Secondary study objectives
Radiographic Stability

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Trident II Tritanium Acetabular Shell for RevisionExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Stryker OrthopaedicsLead Sponsor
78 Previous Clinical Trials
20,430 Total Patients Enrolled

Media Library

Trident II Tritanium Acetabular Shell (Cementless Hip Replacement) Clinical Trial Eligibility Overview. Trial Name: NCT04317586 — N/A
Hip Revision Surgery Research Study Groups: Trident II Tritanium Acetabular Shell for Revision
Hip Revision Surgery Clinical Trial 2023: Trident II Tritanium Acetabular Shell Highlights & Side Effects. Trial Name: NCT04317586 — N/A
Trident II Tritanium Acetabular Shell (Cementless Hip Replacement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04317586 — N/A
~3 spots leftby Dec 2025